Genmab Shares Jump
Genmab shares surged after encouraging clinical-trial results for an experimental colorectal cancer treatment, highlighting how drug-development milestones can reshape biotechnology valuations. European equities also recovered as investors weighed corporate earnings, easing oil prices and upcoming central-bank decisions. │ ◉ Shares surge: Genmab gained 13.7% in Monday trading following encouraging follow-up data from its experimental cancer
Genmab Shares Jump Read More »












